✨ Free AI Report
Alaunos Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Alaunos Therapeutics, Inc.
Company Research

Alaunos Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Alaunos Therapeutics, Inc. stands out in the biopharmaceutical industry with its innovative approach to cancer treatment. The company is dedicated to developing groundbreaking therapies that harness...

Analyst-debate audio for Alaunos Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Alaunos Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Company OverviewProduct PortfolioLeadership and Management TeamFinancial OverviewMarketing StrategiesMarket Overview and Competitors
Get Interactive Report Freeor start reading below
Live on AskCyborg
4/10Mixed
Alaunos Therapeutics, Inc.

High-risk early-stage biotech with dual targeted therapies in large markets, but substantial development and funding risks ahead.

▶︎ Listen to the 90-second analyst debate
4/ 10Mixed

Cyborg Score thesis

High-risk early-stage biotech with dual targeted therapies in large markets, but substantial development and funding risks...

Read the full analyst-debate transcript →
Industry Biopharmaceutical / Cell Therapy
2 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 16, 2026
AI-Generated Research
30+ Page Report

Get the Latest Alaunos Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Alaunos Therapeutics, Inc. stands out in the biopharmaceutical industry with its innovative approach to cancer treatment. The company is dedicated to developing groundbreaking therapies that harness the power of the immune system to target and eliminate cancer cells. Founded with a vision to revolutionize cancer care, Alaunos Therapeutics, Inc. has rapidly advanced in the field, thanks to its robust pipeline and strategic collaborations.

Company Overview

Pro stress-test →

Alaunos Therapeutics, Inc., formerly known as Ziopharm Oncology, Inc., is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative immunotherapies to combat cancer. Headquartered in Houston, Texas, the company leverages its proprietary TCR-T cell therapy platform to create personalized treatments for patients with solid tumors.

Product Portfolio

Pro stress-test →

Alaunos Therapeutics, Inc. offers a range of cutting-edge products aimed at transforming cancer treatment:

  • TCR-T Cell Therapy: This personalized therapy involves engineering a patient’s T cells to express T-cell receptors (TCRs) that specifically target and destroy cancer cells.
  • Sleeping Beauty Technology: A non-viral gene transfer system that enables efficient and cost-effective engineering of T cells.
  • IL-12 Gene Therapy: An innovative approach that uses interleukin-12 to stimulate the immune system to attack cancer cells.

Leadership and Management Team

Pro stress-test →

The success of Alaunos Therapeutics, Inc. can be attributed to its experienced leadership team:

  • Kevin S. Boyle, Sr.: CEO with extensive experience in biopharmaceutical management and finance.
  • Dr. Drew Deniger: Chief Scientific Officer, renowned for his expertise in immunotherapy and TCR-T cell development.
  • Catherine M. Mackey: Chair of the Board, with a strong background in biotechnology and pharmaceutical industries.

Financial Overview

Alaunos Therapeutics, Inc. has shown promising financial metrics, reflecting its growth potential:

  • Revenue Growth: Steady increase in revenue with strategic partnerships and licensing agreements.
  • R&D Investment: Significant investment in research and development to drive innovation and pipeline expansion.
  • Market Capitalization: A strong market presence with a growing investor base.

Marketing Strategies

The company’s marketing strategies are focused on building awareness and establishing its brand in the oncology space:

  • Thought Leadership: Participation in key industry conferences and publishing in scientific journals.
  • Strategic Partnerships: Collaborations with leading research institutions and pharmaceutical companies.
  • Patient Advocacy: Engaging with patient advocacy groups to raise awareness about their therapies.

Market Overview and Competitors

The oncology market is highly competitive, with several key players:

  • Major Competitors: Companies like Adaptimmune, Kite Pharma, and Juno Therapeutics dominate the space.
  • Market Trends: Growing demand for personalized cancer treatments and advancements in immunotherapy.

Sales Strategies

Alaunos Therapeutics, Inc. employs a multi-channel sales approach to reach its target market:

  • Direct Sales: Engaging directly with healthcare providers and institutions.
  • Partnership Sales: Leveraging partnerships with pharmaceutical companies for broader market access.
  • Digital Outreach: Utilizing digital platforms for marketing and patient education.

Technologies Utilized

The company’s innovative technologies are pivotal to its success:

  • TCR-T Cell Technology: Cutting-edge technology for engineering T cells.
  • Sleeping Beauty System: A non-viral gene transfer method.
  • IL-12 Gene Therapy: Utilizing cytokine signaling to boost immune response.

HR Practices

Alaunos Therapeutics, Inc. is committed to fostering a positive work environment:

  • Talent Acquisition: Attracting top talent in the biopharmaceutical industry.
  • Employee Development: Offering continuous learning and development opportunities.
  • Diversity and Inclusion: Promoting a diverse and inclusive workplace culture.

Corporate Responsibility

The company emphasizes corporate social responsibility (CSR) initiatives:

  • Community Engagement: Participating in community health programs and cancer awareness campaigns.
  • Sustainability: Implementing eco-friendly practices in their operations.
  • Ethical Practices: Upholding high ethical standards in clinical trials and patient care.

Future Plans

Alaunos Therapeutics, Inc. has ambitious plans for the future:

  • Pipeline Expansion: Continuing to develop and expand its pipeline of innovative therapies.
  • Global Expansion: Expanding its market presence internationally.
  • Strategic Collaborations: Forming new partnerships to accelerate research and development.

Get the comprehensive report on Alaunos Therapeutics, Inc. by subscribing

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Alaunos Therapeutics, Inc..

+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Alaunos Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Compare Alaunos Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Alaunos Therapeutics, Inc. operates in Biopharmaceutical / Cell Therapy. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biopharmaceutical by Cyborg Score

Browse Biopharmaceutical / Cell Therapy research →
NEW · MCP server

Ask your AI assistant about Alaunos Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Alaunos Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Alaunos Therapeutics, Inc. do this quarter?”
“Is Alaunos Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Alaunos Therapeutics, Inc. do?+
Alaunos Therapeutics, Inc. stands out in the biopharmaceutical industry with its innovative approach to cancer treatment. The company is dedicated to developing groundbreaking therapies that harness...
What is Alaunos Therapeutics, Inc.'s Cyborg Score?+
Alaunos Therapeutics, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Alaunos Therapeutics, Inc.'s main competitors?+
Named competitors include GLP-1 Receptor Agonists (Ozempic/Mounjaro/Zepbound), CAR-T and TCR-T Cell Therapies. The full competitive landscape is in the AskCyborg report.
How can I get the full Alaunos Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Alaunos Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Alaunos Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Company Research

Gambling and Lotteries Industry BriefingStationery and Office Products Industry BriefingDefense Tech Industry BriefingAi Infrastructure Systems Industry BriefingPet Insurance Industry BriefingSelf-Storage Industry BriefingMetal Additive Manufacturing Industry BriefingAi Accelerator Hardware Systems Industry BriefingLuxury Wines & Spirits Industry BriefingEnzymatic Plastic Recycling Industry BriefingInfrastructure as a Service (IaaS) Industry Briefingluxury fashion apparel Industry Briefing

Explore Industry Research

Travel Insurance Industry Company Research ReportSecurity Services Industry Company Research ReportLandscaping and Grounds Maintenance Industry Company Research ReportJanitorial and Cleaning Services Industry Company Research ReportSustainability Consulting Industry Company Research ReportReal Estate Investment Trusts (REITs) Industry Company Research Report
Browse All Company ResearchBrowse All Industry ResearchRSS Feed